Skip to main content

Table 2 Distribution according to the original 2016 ACR/EULAR response criteria for improvement and their modified version

From: The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up

Original 2016 ACR/EULAR response criteria for adult myositis of minimal (≥20 points), moderate (≥40 points), and major (≥60 points) improvement according to the Total Improvement Score (range 0–100) based on six core set measures: physician’s global activity (range 0–20), patient’s global activity (range 0–10), extramuscular disease activity (range 0–20), MMT (range 0–32.5), HAQ (range 0–10), and enzyme levels (range 0–7.5). However, the percentage distribution of patients in each category was calculated only from MMT-8, HAQ, and CK, thus amounting to a maximum Total Improvement Score of 50

Interval (weeks)

Category of improvement (points)

Intervention group (% of patients)

Control group (% of patients)

p-value for each category

p-value for overall distribution

0–12

Least improvement (0–19) or worsening

48

100

<0.001

<0.001

Minimal improvement (20–39)

52

0

<0.001

Moderate improvement (40–59)

0

0

NA

Major improvement (≥60)

0

0

NA

0–24

Least improvement (0–19) or worsening

11

100

<0.001

<0.001

Minimal improvement (20–39)

78

0

<0.001

Moderate improvement (40–59)

11

0

<0.001

Major improvement (≥60)

0

0

NA

0–48

Least improvement (0–19) or worsening

44

91

<0.001

<0.001

Minimal improvement (20–39)

52

9

<0.001

Moderate improvement (40–59)

4

0

0.046

Major improvement (≥60)

0

0

NA

Modification of the original 2016 ACR/EULAR response criteria for adult myositis with minimal (≥10 points), moderate (≥20 points), and major (≥30 points) improvement due to the maximum Total Improvement Score of 50, as a sum of only three core set measures: MMT-8, HAQ, and CK, which better characterizes the overall improvement based on these three outcome measures

Interval (weeks)

Category of improvement (points)

Intervention group (% of patients)

Control group (% of patients)

p-value for each category

p-value for overall distribution

0–12

Least improvement (0–9) or worsening

4

100

<0.001

<0.001

Minimal improvement (10–19)

44

0

<0.001

Moderate improvement (20–29)

44

0

<0.001

Major improvement (≥30)

8

0

0.004

0–24

Least improvement (0–9) or worsening

0

83

<0.001

<0.001

Minimal improvement (10–19)

15

17

0.689

Moderate improvement (20–29)

44

0

<0.001

Major improvement (≥30)

41

0

<0.001

0–48

Least improvement (0–9) or worsening

11

78

<0.001

<0.001

Minimal improvement (10–19)

33

13

0.001

Moderate improvement (20–29)

41

9

<0.001

Major improvement (≥30)

15

0

<0.001

  1. Acronyms: Statistically significant differences (p < 0.05) are marked in bold
  2. ACR American College of Rheumatology, EULAR European League Against Rheumatism, MMT Manual Muscle Testing, HAQ Health Assessment Questionnaire, MMT-8 MMT assessing eight muscle groups, CK creatine kinase NA not applicable